Preliminary quantitative proteomics analysis in chronic and latent Keshan disease by iTRAQ labeling approach

Yuxiao Sun¹, Chuanyu Gao¹, Xianqing Wang¹ and Yuhao Liu¹

¹Department of Cardiology, Zhengzhou University, People’s Hospital, Zhengzhou, Henan 450003, PR China
²Department of Cardiology, Henan Provincial People’s Hospital, Zhengzhou, Henan 450003, PR China

Correspondence to: Chuanyu Gao, email: chuanyugao2017@163.com

Keywords: Keshan disease; iTRAQ; proteomics; DEPs; biomarker

Received: August 12, 2017  Accepted: October 05, 2017  Published: November 11, 2017

Copyright: Sun et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Keshan disease is a congestive cardiomyopathy. Dietary selenium deficiency combined with additional stressors are recognized to cause the cardiomyopathies. In this study, clinical condition of individuals with different subtypes including chronic and latent were analyzed. ECG abnormalities, chest radiography, echocardiography and blood selenium concentration were assessed. Subsequently, in effort to uncover proteins that were reliably changed in patients, isobaric tags for absolute and relative quantitation technology was applied. Bioinformatics analysis of the differentially expressed proteins were performed by means of Gene Ontology classification, KEGG pathway, and Ingenuity Pathway Analysis. ELISA experiment was used to detect the interesting proteins. As a result, chronic patients showed more ECG abnormalities compared to Latent. All patients had low blood selenium level. Proteomics data revealed 28 differentially expressed proteins. By ELISA variation, LGALS3BP was increased in chronic patients. PZP was elevated specially in latent patients. The above results might be beneficial for further biomarkers discovery and Keshan disease pathological mechanism study.

INTRODUCTION

Keshan disease (KD) is a form of endemic cardiomyopathy (ECD) that affects the heart muscle with unknown etiology. The pathological features include multifocal necrosis cardiogenic shock, arrhythmia, cardiomegaly, and replacement fibrosis of the myocardium, resulting in acute or chronic congestive heart failure. KD mainly occurs in China, involving 327 counties of 16 provinces [1]. The incidence rates are rising steadily over the past decades [2]. It’s a potentially life-threatening condition and particularly widely prevalent in women and children. Clinically, KD patients are divided into four categories (acute, subacute, chronic, and latent) based on the onset of attack, clinical features, and heart function. The main subtypes are chronic and latent KD (CKD and LKD). CKD usually has insidious onset and slow progression. In terms of clinical characteristics, CKD is similar to dilated cardiomyopathy (DCM), but CKD patients have severe myocardial degeneration, evident necrosis and fibrosis, and even clear geographic features [3]. LKD is usually asymptomatic and shows mild heart enlargement with normal heart function [4].

Dietary low selenium (Se) is associated with a cardiomyopathy, myopathy and osteoarthropathy [5]. Se deficiency is considered the direct cause for KD. But how to explain the seasonal and annual variation of the disease occurrence? Moreover, not all Se deficiency regions emerge KD cases. Recent years strong evidences discuss that other factors, such as coxsackievirus B (CVB) and vitamin E (VE), contribute to KD etiology [6-8]. The incidence is likely affected by a synergistical result of various etiological factors together, including soil and water, nutrition, viral infection, geological and chemical (Se deficiency) factors. To explore the potential mechanism, molecular analysis should be performed.
Quantitative proteomics have been applied to identify all the differentially expressed proteins (DEPs) in a complex mixture, which may help us understand the changes in disease oncogenesis [9]. Quantitative proteomics in heart disease disclosed that clinical outcome and risk evaluation was related to protein expression closely [10]. Recently the lectin microarray method showed the significant differences in serum glycosylation characteristics among CKD and LKD patients [11]. Thus, we think expression pattern of serum protein will give us more broad implications to KD.

Isobaric tags for absolute and relative quantitation (iTRAQ) is a mass spectrometry technology that 4 or 8 analysis samples can be quantified simultaneously in a single mass spectrometric analysis. By measuring reporter ions peak intensities of tagged peptides during MS/MS, it accurately and sensitively provides quantitative information including affinity pull-downs, time-course analyses, and elucidation of disease markers [12, 13]. Recently we have detected the CKD proteomics using iTRAQ technique and compared the protein changes with local healthy controls [14]. Aiming to expand the understand of KD, the current study collected LKD patients and controls outside the endemic areas. Epidemiological features were assessed. iTRAQ coupled with 2D-nanoHPLC-ESI-MS/MS was applied to further compare the global protein profile between CKD and LKD. The workflow of iTRAQ proteomics analysis was described in Figure 1.

RESULTS

Clinical baseline data of study population

The characteristics of the subjects was shown in Table 1. 31 CKD patients consisting of 17 males and 14 females with mean age 46.8 ± 9.1 years, exhibited poor heart function. The difference of age and gender had no statistical significance. Referring to the NYHA cardiac function classification method, most CKD patients belonged to NYHA class III (12, 38.7%) and class IV (12, 38.7%). 40 LKD patients consisted of 18 males and 22 females and mean age of them was 45.7 ± 11.8 years. 24 (60%) of the LKD patients showed class I with normal heart function. As the survivors experienced KD outbreak period, these patients had higher family history rate than healthy residents in affected areas. Epidemiological features were assessed. iTRAQ coupled with 2D-nanoHPLC-ESI-MS/MS was applied to further compare the global protein profile between CKD and LKD. The workflow of iTRAQ proteomics analysis was described in Figure 1.

Identification and relative quantification of DEPs

Epidemiologic feature of population participated in proteomics experiments were listed in Table 3. In the pooled serum protein sample, we identified a total of 329 proteins, of which 146 were quantified and contained at least one unique peptides (confidence interval>95%, p<0.05). Using EXC reporter ion m/z 121 as control, further relative quantification in each group was executed. After removing the repetitive redundant proteins, fold changes were calculated. Definitively, combined with our published data, 28 proteins had different expression profile between the four groups (Table 4). Filtered with exclusion parameters, fold changes >1.2 or <0.5 were considered significant.

A sharp increased level of LGALS3BP was observed in KD, especially in CKD. Individuals in endemic regions had a high PZP concentration, particularly in LKD. But compared to INC and LKD, PZP in CKD was decreased. The Venn-diagram in Figure 3 shows the overlap of significantly DEPs among CKD, LKD and INC compared to EXC. Respectively, there were 3 proteins (CIQB, CP, APOA2) remarkably altered in CKD and 3 (F5, SERPINC1, CFH) in LKD.
Bioinformatics analysis of DEPs

By Go functional analysis, the 28 proteins were divided into 3 categories using DAVID v6.7: molecular functions, biological processes and cellular component. In Figure 4A, for biology progress, the main terms were platelet degranulation \( (p=4.20E^{-11}) \), negative regulation of endopeptidase activity \( (p=1.30E^{-10}) \) and regulation of complement activation \( (p=5.90E^{-08}) \). For cellular component, majority of the proteins were involved...
in blood microparticle (83%), extracellular region (100%), extracellular exosome (91%). In respect to molecular function, they were associated with serine-type endopeptidase inhibitor activity ($p=1.10\times10^{-7}$), heparin binding ($p=1.30\times10^{-6}$) and endopeptidase inhibitor activity ($p=1.60\times10^{-5}$). Pathway enrichment analysis showed

Figure 1: Flowchart of iTRAQ proteomics approach.

Table 3: Baseline characteristics of the enrolled subjects in iTRAQ

| Groups | CKD N=10 | LKD N=10 | INC N=10 | EXC N=10 |
|--------|----------|----------|----------|----------|
| Age, yrs | 48.7±8.1 | 44.9±11.1 | 44.2±13.5 | 43.1±11.5 |
| Female/male | 6/4 | 5/5 | 5/5 | 5/5 |
| Blood selenium(μg/ml) | 0.065±0.017* | 0.067±0.016 | 0.093±0.014 |
| Family history of KD (%) | 4 (40)* | 1(10) | - | - |
| NYHA class, n (%) | | | | |
| I | 0 (0)* | 8(80) | - | - |
| II | 1 (10)* | 2(20) | - | - |
| III | 4 (20)* | - | - | - |
| IV | 5 (50)* | - | - | - |
| Systolic BP(mmhg) | 111±15* | 117±12 | 120±17 | 123±15 |
| Diastolic BP(mmhg) | 72±9 | 79±7 | 77±9 | 80±8 |
| Cardiothoracic ratio | 0.63±0.06* | 0.47±0.03 | 0.45±0.04 | 0.44±0.44 |
| Echocardiography | | | | |
| LVEF (%) | 36.43±10.08* | 56.12±10.64 | 64.31±8.12 | 67.18±7.54 |
| $V_e/V_A$ | 1.32±0.29* | 1.44±0.65 | 1.47±0.68 | 1.62±0.34 |

*a p<0.05, *p<0.01, **p<0.001.
Figure 2: Clinical baseline data of study population. (A) Chest radiography examination reflected the extent of cardiac enlargement. (B, C) Echocardiography results. (D) Blood selenium level in KD patients and controls at baseline. * Compared to INC, \( p < 0.05 \); # comparison in the 3 groups, \( p < 0.01 \); △ compared to KD, \( p > 0.05 \).
| GI_Number    | Protein name                                      | Abbreviation   | Fold change   | Unique peptides | SC (%) | Protein score |
|--------------|--------------------------------------------------|----------------|---------------|----------------|--------|---------------|
|              |                                                  |                | CKD/INC      | CKD/EXC       | LKD/INC| LKD/EXC       | CKD/LKD| INC/EXC       |               |
| gi5031863    | Galectin-3-binding protein                       | LGALS3BP       | 3.352241 3.725793 1.47615 1.881961 1.980342 1.347234 | - | 4 | 68.63 | 217 |
| gi62871078   | Immunoglobulin alpha heavy chain variable region |                | 1.515717 1.827663 1.443929 1.283426 0.913831 | 9 | 12.34 | 162 |
| gi10636875   | Immunoglobulin heavy chain variable region       |                | - 1.36604 1.197479 1.526259 1.319508 0.888843 | 7 | 28.04 | 218 |
| gi31397      | Fibronectin precursor                            | FN1            | 1.292353 1.180993 1.239708 1.156688 1.035265 | 46 | 21.56 | 1620 |
| gi1620909    | Ceruloplasmin                                    | CP             | 1.265757 1.248331 | - | 2 | 8.05 | 138 |
| gi177870     | Alpha-2-macroglobulin precursor                  | A2M            | 1.265757 1.06437 1.34744 0.806642 | 3 | 11.53 | 247 |
| gi573114     | C1q B-chain precursor                            | C1QB           | 1.248331 1.239708 | - | 4 | 25.71 | 101 |
| gi4502261    | Anti-thrombin-III precursor                      | SERPINC1       | 1.148698 0.882703 1.375553 1.257013 0.697372 | 27 | 41.16 | 650 |
| gi7744385    | Complement factor H                              | CFH            | 1.148698 1.042466 2.114036 2.056228 1.526259 | 4 | 9.5 | 281 |
| gi41388180   | Monoclonal IgM antibody heavy chain               |                | 1.14064 1.079222 1.205808 0.888843 1.021012 | 26 | 30.85 | 615 |
| gi115298678  | Complement C3 precursor                          | C3             | 1.125085 0.933033 1.337928 1.042466 0.920188 | - | 99 | 43.48 | 2549 |
| gi37138      | Unnamed protein product                          | THBS1          | 1.071773 0.773782 1.180993 1.189207 0.870551 0.707107 | 7 | 12.65 | 375 |
| gi182412     | Coagulation factor V precursor                   | F5             | 1.049717 0.97942 1.613284 1.231144 0.806642 | 2 | 3.82 | 172 |
| gi130675     | Serum paraoxonase/arylesterase 1                 | PON1           | 1.028114 1.117287 1.148698 1.125085 1.071773 | 7 | 33.24 | 328 |
| gi178849     | Apolipoprotein E                                 | APOE           | 1.082635 0.864537 0.882703 0.986233 | 41 | 52.05 | 735 |
| gi33989      | Inter-alpha-trypsin inhibitor heavy chain        | ITIH1          | 1.197479 1.301342 | 8 | 32.13 | 229 |
| gi2258128    | Complement 9                                     | C9             | 0.607097 0.835088 0.532185 0.721965 1.132884 1.310393 | 2 | 6.75 | 106 |
| gi33985      | Trypsin inhibitor                                | ITIH2          | 0.773782 1.265757 1.057018 0.852635 1.140764 1.248331 | 3 | 13 | 279 |
| gi1655598    | Lipopolysaccharide binding protein               | LBP            | 0.864537 0.876606 0.107922 0.71773 0.586417 | 9 | 17.05 | 271 |
| gi190026     | Plasminogen                                      | PLG            | 0.888843 1.414214 0.757858 1.180993 1.172835 1.515717 | 2 | 11.36 | 144 |
| gi13477169   | Vitronectin                                      | VTN            | 0.895025 1.021012 1.156688 1.057018 | 54 | 26.15 | 449 |
| gi42716297   | Clusterin isoform 1                              | CLU            | 0.913831 0.97942 0.926588 0.972655 1.069696 | 42 | 27.15 | 458 |
| gi35825      | Pregnancy zone protein                           | PZP            | 0.913831 1.392352 1.603851 3.961702 0.659754 2.173470 | 2 | 47.89 | 199 |
| gi35825      | Proapolipoprotein                               | APOA1          | 0.920188 1.021012 0.933033 | 1 | 148 | 70.68 | 868 |
| gi178775     | Unnamed protein product                          | F2             | 0.965936 0.876606 0.870551 0.82932 | 40 | 37.14 | 907 |
| gi189066554  | C4b-binding protein alpha chain precursor        | C4BPA          | 0.972655 1.042466 1.057018 0.933033 0.965936 | 9 | 23.45 | 333 |
| gi4502503    | Alpha-1-antitrypsin                              | SERPINA1       | 0.993092 0.558644 2.20381 1.210335 0.450625 0.532185 | 2 | 34.21 | 240 |
| gi4502149    | Apolipoprotein A-II preproprotein                | APOA2          | 1.464086 | - | 9 | 54 | 174 |

"-" means no data.
that 28 DEPs participated in 8 pathways. Among them, Complement and coagulation cascades (ko04610) covered 11 proteins (A2M, F2, F5, C1QB, C3, C9, C4BPA, CFH, PLG, SERPINA and SERPINC). The networks analysis and signaling pathway annotations were computed by IPA tools. These proteins were shown to be involved in 5 key protein-protein interaction networks ranged between 34 and 2 (Table 5 and Figure 4B). The primarily clustered network (score 34) containing 15 focus molecules (A2M, APOA1, APOA2, APOE, C3, C9, CFH, CP, F2, F5, FH1,

Figure 3: Venn diagram of significantly DEPs compared to EXC. The numbers in each large circle represented the total number of proteins among various combinations; the overlap represented common proteins. Probable biomarkers within our results were exhibited.
PLG, SERPINA1, SERPINC1 and VTN) was displayed in Figure 4B. Pathway category was displayed in Figure 4C. Acute phase response signaling, LXR/RXR activation, coagulation system and complement system, and Extrinsic prothrombin activation pathway were the top 5 pathway annotations.

**ELISA detection**

Galectin-3 binding protein (LGALS3BP) and Pregnancy zone protein (PZP) were selected for quantitative proteomic analysis verification using ELISA (n = 20). Differences between the four groups (p < 0.05) were noted. The results were consistent with iTRAQ in Figure 5. Expression level of LGALS3BP in CKD (100.72±19.97 ng/ml) was up-regulated significantly when compared with LKD, INC and EXC. While the expression of PZP was significantly increased in LKD (2439.15±533.67 pg/m) compared with CKD, INC and EXC (p <0.05).

**DISCUSSION**

Clinical data provided important reference and guidance for KD diagnose. CKD remains a higher mortality and always developed from untreated LKD patients [15]. Almost all CKD cases exhibit severe abnormal ECG changes in present study. For KD inspection, ECG measurement is a common method. Besides, ECG has high sensitivity for CKD risk prediction in LKD. Previous studies have demonstrated that the presence of major ECG abnormalities among LKD was associated with a higher risk of CKD [4]. In our investigation, junctional tachycardia, complete bundle branch block, intraventricular block, ventricular hypertrophy, and atrial flutter were considered as major abnormalities. The criteria for minor prevalent ECG abnormalities were premature beats and incomplete bundle branch block. The 41 LKD patients mainly showed atrial premature beats, ventricular premature beat (VPB), incomplete right bundle branch block and ST-T changes. Several cases showed complete right bundle branch block and intraventricular block (class I). X-chest radiography and echocardiography provides important application value for KD progresses. Severe cardiac enlargement, obvious pulmonary congestion, decreased apex beat and a significantly increased CT ratio were found in CKD patients. But in terms of the imagological examination, CKD is not obvious difference from DCM symptoms. Epidemiological characteristics including extent of valvular regurgitation and cardiac function index are of great value for KD identification from other myocardial disorders.

CKD patients suffered from severe myocardial degeneration, necrosis and fibrosis. Obviously decreased LVEF of the 31 CKD patients indicated that their heart systolic function was damaged, which may increase the heart preload to maintain the effective stroke volume via Starling’s law. Long-term heart injury exacerbates cardiac chambers enlargement and cardiac compensatory
decompensation. Elevated Tei value reflects the impaired left ventricle. For LKD, the heart cavity is slightly enlarged. 57.5% patients have mild mitral regurgitation. There were no evident difference on LVEF and VE/VA compared to CKD and normal group, but the Tei value is significantly raised. The result hinted that slight damage appeared during compensated stage in LKD patients. Tei index is more sensitivity to detect mild cardiac dysfunction in early stage of LKD.

KD patients participated in our investigation presented low blood Se. Se-deficiency induced decreased activities of selenium-dependent antioxidant enzymes such as GPx1 and TrxR1 [16, 17]. Excessive oxidative stress was positively correlated with the degree of myocardium

Table 5: IPA Networks ranking with relative molecules symbols

| ID | Molecules in network | Score | Focus molecules | Top functions |
|----|----------------------|-------|-----------------|--------------|
| 1  | A2M, Akt, APOA2, APOE, C3, C9, calpain, CFH, chymotrypsin, Collagen type IV, Collagen (s), CP, Ecm, elastase, F2, F5, Fibrin, Fibrinogen, FN1, HDL, HDL-cholesterol, Intergrin, Laminin, LDL, MAC, Map, Pld, PLG, Pro-inflammatory Cytokine, Serine Protease, SERPINA1, SERPINC1, trypsin, VLDL-cholesterol, VTN BRAF, chemokine, CPL7A1, DHCR24, ERK1/2, gelatinase, HRG, IgG, IL1, IL12 (complex), IL12 (family), ILR1, Immunoglobulin, indicant, Jnk, LBP, LGALS3BP, Mapk, MIR320, MMP10, NFkB (complex), P38MARK, Pak, Pdgf (complex), PI3K (complex), Pka, Pld, Rac, SERPINC1, SERPINF2, Tgf beta, THBS1, TLR2/TLR4, Vegf | 34 | 15 | Cellular Movement, Hematological System Development and Function, Immune Cell Trafficking |
| 2  | Iti, ITIH1, ITIH2, ITIH3, ITIH4 | 5 | 3 | Cancer, Endocrine System Disorders, Carbohydrate Metabolism |
| 3  | APOA1, APOE, CD47, CD59, ed59a, CTSD, cyclic GMP, dihydrotestosterone, EDN1, F2, Hba, HBB, Hbb-b2, heme, hemoglobin, HIF1A, HMOX1, homocysteine thiolactone, HP, IL10RB, iron, ITGB3, JAK2, lipid, MIF, NO53, NR2C2, PdgfB, SCARB1, SLC40A1, SMAD7, SNAI2, SOD1, SPP1, TNFRSF9 | 5 | 3 | Cardiovascular Disease, Hereditary Disorder, Metabolic Disease |
| 4  | C1q, C1QB, DMP1, DYF5, PPARα, PPARδ, PSEN1, PSEN2 | 5 | 3 | Hematological System Development and Function, Hematopoiesis, Tissue Morphology |
| 5  | | 2 | 1 | Organ Morphology, Hair and Skin Development and Function, Hereditary Disorder |

The statistical likelihood (score) was used to rank the networks. Score value, number of molecules and top function for each network were listed.

Figure 5: Protein serum concentration of LGAL3BP and PZP in the four groups. *p<0.01 vs other groups.
damage. Although epidemiologic studies have assessed the 
prevalence of KD and chronic exposure to environmental 
Se [18, 19], alternative etiologic hypotheses discussed it’s 
possibly being a cofactor or simply an innocent bystander. 
This is what we need to think deeply. Notwithstanding 
LKD have a high prevalence rate, since hidden onset and 
asymptomatic character, the surveillance and diagnosis 
usually needs a long-term follow-up and clinical 
monitoring [20]. Traditional methods such as ECG, 
X-ray and echocardiography are not enough to predict the 
exacerbation. Therefore, prevention efforts could focus 
on the KD pathogenesis. Proteomic studies of KD have 
been conducted by two-dimensional gel electrophoresis, 
ClinProt Technique and microarrays [21-23]. Given 
meaningful proteins are masked by the high-abundant 
proteins (HAPs) in serum, LAPs detection is pivotal. 
ProteoMiner Protein Enrichment protocol is an effective 
strategy to capture serum LAPs [24]. In addition, the 
iTRAQ shot-gun approach offer us a better option with 
higher sensitivity.

Expression profile of the 28 identified proteins 
changed apparently in KD subtypes. Basing on KEGG 
database, 47.8% of the proteins were linked to the 
coagulation and complement cascades. The cascades 
appear to be triggered simultaneously by severe tissue 
injury, acute trauma, or during systemic inflammation 
[25]. We suggested that its activity was led by the damaged 
myocardial cells.

Moreover, increasing levels of complements, CP 
and C1QB were seen only in patients with CKD. CP had 
ability to evaluate the activity of vascular inflammation 
and pathophysiological processes of heart failure (HF) [26, 
27]. C1QB is discovered as part of C1 and participates in 
a variety of cellular processes independent of complement 
activation, such as innate and adaptive immunity and wound 
repair [28]. The C1QB functions in impaired myocardium 
may be worth studying. Elevated serum level of LGALS3BP 
was detected in both CKD and LKD. Especially in CKD, 
who suffer from more severe myocardial fibrosis, the rising 
fold changes reached to 3.352241 and 3.725793 versus INC 
and EXC respectively. Compared to LKD, LGALS3BP in 
CKD was also significantly raised (1.980342). LGALS3BP 
was frequently reported to be a critical inflammatory 
mediator for anti-virus and anti-bacteria immune responses 
[29]. Recently studies suggested LGALS3BP involved in 
potentiate monocyte-derived fibrocyte differentiation and 
late fibrosis was characterized by an increased LGALS3BP 
[30]. Combined with the clinical characteristics, the current 
work indicate LGALS3BP may be a predictor assessing 
CKD fibrosis severity. But the result needs further study on 
a large-scale sample size to confirm.

SERPINC1 and F5 increased in LKD, but in 
CKD, they decreased. SERPINC1 is the most important 
coagulation factor inhibitor and suppress inflammation. 
SERPINC1 deficiency caused Thromboembolic. 
Numerous studies proved that reduced SERPINC1 have 
a superiority in predicting many disorders (e.g. heart 
failure, kidney diseases) [31, 32]. Upregulation of PZP 
in LKD was first revealed in present study. PZP and its 
homologous glycoprotein A2M were also considered 
inhibitors of coagulation [33]. High SERPINC1 and 
PZP level reflects LKD patients may have a lower risk of 
vascular embolization. Unlike SERPINC1, PZP is 
quantitatively an important pregnancy-associated protein 
and strongly influenced by hormones. But we guaranteed 
that there were no participates during pregnancy 
or under hormonal treatment. It is an interesting 
 discovery. Svendsen P et al found that PZP intravenous 
significantly prolonged the survival of heterotropic A/J 
heart heart transplants in A.CA mouse recipients. [34] In 
2016, John D. Eicher et al conducted RNA-seq studies 
on 9,565 platelets transcripts from 32 acute myocardial 
infarction (MI) patients. The data displayed higher PZP 
expression in NSTEMI platelets than STEMI [35]. 
Beyond that, PZP was rarely reported to have correlation 
with any myocardial diseases. Based on fact that PZP 
has been found elevated in numerous inflammatory 
states and evidence that elevated PZP eventually evoke 
the collagen reactivity [36], we present PZP exerts an 
unspecific immunosuppressive effect in dysregulated 
cardiomyocytes. Since the low degree of myocardial 
fibrosis in LKD, we deem PZP may delay the 
appearance of corresponding symptoms in some extent. 
However, perennial inflammation progress in CKD may 
fluence PZP expression. This hypothesis needs to be 
further demonstrated.

In summary, clinical characteristics and KD 
proteomics in chronic and latent subtypes were 
investigated. The present study is the first to compare 
the proteome in CKD and LKD using iTRAQ method. 
We found LGALS3BP increased distinctly in CKD. PZP 
increased in LKD but decreased in CKD. ELISA test 
certified it. Our findings contribute a prospective insight 
to KD molecular mechanism.

LIMITATIONS

Because of some restriction in our research, there 
are limitations and deficiency to the present study. First, 
the serum sample size for proteomic analysis is small, 
large-scale of patient samples await a long-term collection 
and perform. Involvements of acute or subacute KD cases 
would provide more enlightenment. Then, the related 
signaling pathways and potential biomarker needs more 
samples and clinical experiments to confirm.

MATERIALS AND METHODS

Study population

A total of 131 participates were recruited for the 
clinical characteristics investigation. 31 CKD patients and
40 LKD patients from severe KD endemic areas Yunyi County and Huangling County (Shaanxi, China) were filtered with strict clinical criterion in new “National Criteria for Diagnosis of the Keshan Disease” (WS/T210-2011) promulgated by National Ministry of Health. The patients were newly or past diagnosed as Keshan disease with a long-term follow-up. 30 internal volunteers (INC) from KD endemic areas and 30 external volunteers (EXC) presented at Physical Examination Department of the second affiliated hospital of Xi’an Jiaotong University (Shaanxi, China) were collected as healthy controls. They matched with KD patients for age and gender (detailed data were presented in Table 1). For iTRAQ based quantitative proteomics analysis, blood samples from 20 KD patients including 10 CKD and 10 LKD, 20 healthy controls including 10 INC and 10 EXC were obtained.

Ethics approval was granted by the ethics committee of the second affiliated hospital of Xi’an Jiaotong University. Signed informed consent was obtained from all participants (or their legal guardians). KD patients and INC individuals must have lived in the KD-affected areas for consecutive period of at least six months. Individuals were excluded if they met any of the criteria described below:

i dilated cardiomyopathy patients;
ii bone metabolic disease patients and kidney disease patients;
iii high blood pressure, coronary heart disease, diabetic pulmonary fibrosis;
v being pregnant or lactating;
v other chronic diseases.

Clinical evaluation

Physical examination, standard 12-lead electrocardiography (ECGs, ECG-1250C/P, JAPAN), chest radiography (Simens, Germany) and echocardiography (Paker SonoNet-3D, USA) were performed at baseline in KD patients and internal healthy subjects strictly using standardized procedures. Cardiac functions of all the endemic area subjects were classified referring to the NYHA (New York heart association) classification method. The average values of 3 consecutive cardiac cycles were taken for all the measurements.

Specifically, the criteria for prevalent ECG abnormalities in KD patients were any of the following: premature beats, junctional tachycardia, (left and right) bundle branch block, intraventricular block, ST-T changes, ventricular hypertrophy, atrial flutter, and QTe prolongation. Participants with no ECG abnormalities were classified as normal ECG. Cardiothoracic ratio (CT ratio) was measured to determine the extent of cardiac enlargement. Normal CT ratio ≤0.50. Cases with CT ratio >0.50 were diagnosed as cardiac enlargement: 0.51-0.55 were classified as mild enlargement, 0.56-0.60 were classified as moderate enlargement, >0.60 were classified as severe enlargement. As for echocardiography evaluation, mitral inflow velocity in early diastole (VE) and late diastole (VA) were obtained. Left ventricular diastolic function were estimated using their ratio (VE/VA) and left ventricular systolic function was evaluated by left ventricular ejection fraction (LVEF). Tei is a comprehensive index of reflecting cardiac systolic and diastolic functions. 5ml fasting venous blood samples of all the participates were collected and serum was obtained through centrifugation at 4,000 rpm for 10 min and stored at -80°C. Serum selenium concentrations were measured using a fluorescence spectrophotometric method (XDYG2A; AODI Detection Instrument CO., Beijing, China).

Protein preparation, iTRAQ labeling and SCX fractionation

According to the manufacturer’s instructions, serum samples of the 40 subjects were processed using ProteoMiner™ Protein Enrichment Systems (Bio-Rad, USA) to reduce the complexity and enrich the low-abundance proteins (LAPs). Protein samples were denatured using 20ul solution buffer and 1ul 2% SDS, reduced using 10mM DTT at 56°C for 1h, alkylated using 55mMIA in darkness for 1h, and then precipitated within chilled acetone (4×volume) for 2h. After being centrifuged at 20,000g for 30min, the pellet was next dissolved in 1%SDS and 50% TEAB (9×volume). Protein concentrations were determined using 2D Quant Kits (GE Healthcare, Buckinghamshire, UK). Removal efficiency of high-abundance proteins was detection by SDS-PAGE gel. Samples were digested using Trypsin (sigma, USA) at 37°C for 24h (protein: trypsin = 25:1). Digested peptides were lyophilized to complete dryness and stored at -80°C until needed.

iTRAQ labeling was carried out with an iTRAQ® Reagent-8Plex Multiplex Kit. (Applied Biosystem, Foster City, CA) according to manufacturer’s protocol. Each lyophilized sample (100ug) was dissolved in 0.5M TEAB and added with 70ul isopropyl alcohol. Peptides were labeled with respective isobaric tags (114 for CKD; 116 for LKD; 118 for INC; 121 for EXC), incubated for 2 h, and blend. 10×volume buffer A (10mM KH2PO4, 25% ACN, pH3.0) was mixed to labeled peptides. The pooled sample was then fractionated using Phenomenex Luna 5u SCX 100A (250×4.6 mm, Micron Phenomenex, USA) at a flow rate of 1.0 mL /min with Buffer A and Buffer B (Buffer A with 2M KCl). SCX Fractionation was followed by a C-18 reversed phase (RP) nano-column (100μm,75um, 5micron, Micron Technology, Boise City, USA) elution using an Proxeon Easy nano-LC system (Proxeon, Thermo, USA) at a flow rate of 300 nL/min with buffer A (95%water, 95% acetoniitile,0.1%formic acid) and buffer B (95% acetoniitile,5%water,0.1%formic acid). A continuous linear binary acetoniitile gradient was applied: 5% Buffer 8in 0-80min; 45% buffer B in 80-
85min; 80% buffer B in 85-105min; 5% buffer B in 105-120min, stop. Ultimately, 17 tubes of fractions separated from the column were vacuum concentrated.

**ESI-MS/MS proteomic analysis and data screening**

The peptides were subjected to nano-electrospray ionization followed by tandem mass spectrometry (MS/MS) in a Q-TOF coupled online to the HPLC system. The 3 most intense precursors from MS1 spectra were applied for MS2. Survey scans were acquired from m/z 50 to 3000. The original MS/MS file data were collected with micro TOF-Q control (Bruker, Germany) and submitted to DataAnalysis4.0, from which raw data was converted to MGF file. The Mascot search software (Matrix Science, London, UK) were used to identify and quantify the peptides. The Mascot search parameters were as follows: Enzyme: trypsin; Database: NCBInr_human; Peptide Charge:(1+, 2+ and 3+); Instrument: ESI-QUAD-TOF; Mass values: monoisotopic; Peptide mass tolerance: ±1Da; Fragment mass tolerance: ±1Da; Sample Type: iTRAQ 8plex (Peptide Labeled); Data format: Mascot generic; Fixed modification: carboxymethyl (C); Variable modifications: Gln->pyro-Glu(N-term Q), Oxidation(M), iTRAQ8plex(K), iTRAQ8plex(Y), iTRAQ8plex (N-term).

To reduce the probability of false peptide identification, only peptides with significance scores (≥ 40) at the 95% confidence interval were counted as identified. At least one unique peptide was involved in each confidently identified protein. The fold change cutoff ratio < 0.8 or >1.2 was determined to designate differential expression proteins \( p < 0.05 \) [37].

**Bioinformatics analysis**

Identified proteins were imported the online software DAVID (https://david.ncifcrf.gov/) to perform gene ontology (GO) analysis. GO terms were annotated on the following three aspects: molecular function, cellular component, and biological process. Pathway enrichment based on KEGG pathway database uncovered the enriched pathways of altered proteins. Additionally, the biological network and pathway analysis of these proteins were performed using Ingenuity Pathway Analysis software (IPA, www.ingenuity.com), which is based on the published literatures.

**Protein expression verification by ELISA**

To verify the iTRAQ results, the serum levels of selected proteins were detected using an ELISA quantitation kit (Cusabio, Wuhan, China) following protocols recommended by the manufacturer. Triplicate samples were measured in random order.

**Statistical analysis**

Continuous variables are described by means ± SD. SPSS13.0 software (IBM, Armonk, NY, USA) was used for statistical treatment of clinical data. Comparisons between groups were performed using \( \chi^2 \) test for categorical variables and Student’s t-test for continuous variables. Two-sided \( p \) value<0.05 was statistically significant.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest to report.

**FUNDING**

This work was supported by grants from National Natural Science Foundation of China (30972557). We are grateful to all the patients and individuals who participated in the study.

**REFERENCES**

1. Zhou B, He S, Wang X, Zhen X, Su X, Tan W. Metabolism of arachidonic acid by the cytochrome P450 enzyme in patients with chronic Keshan disease and dilated cardiomyopathy. Biomed Rep. 2016; 4:251.
2. Lei Y, Liu Z, Zhao J, Zhu Y. [Dynamic observation on the relationship between the Keshan disease incidence and some element in internal and external environment in Shanxi Province]. [Article in Chinese]. Wei Sheng Yan Jiu. 2007; 36:433.
3. Lei C, Niu X, Wei J, Zhu J, Zhu Y. Interaction of glutathione peroxidase-1 and selenium in endemic dilated cardiomyopathy. Clin Chim Acta. 2009; 399:102-108.
4. Zhu Y, Lai B, Niu X, Wei J, Tan W, Wang X. Long-term prognostic value of major and minor ECG abnormalities in latent Keshan disease with suspect chronic Keshan disease. J Epidemiol. 2014; 24:385.
5. Burke MP, Opeskin K. Fulminant heart failure due to selenium deficiency cardiomyopathy (Keshan disease). Med Sci Law. 2002; 42:10.
6. Liu Y, Chiba M, Inaba Y, Kondo M. [Keshan disease--a review from the aspect of history and etiology]. [Article in Japanese]. Nihon Eiseigaku Zasshi. 2002; 56:641.
7. Cermelli C, Vinceti M, Scaltriti E, Bazzani E, Beretti F, Vivoli G, Portolani M. Selenium inhibition of Coxsackie virus B5 replication: implications on the etiology of Keshan disease. J Trace Elem Med Biol. 2002; 16:41-46.
8. Tong W, Wang F. Alterations in rat pancreatic islet beta cells induced by Keshan disease pathogenic factors: protective action of selenium and vitamin E. Metabolism. 1998; 47:415-419.
9. Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourkas S, Tamvakopoulos C. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res. 2008; 7:3146-3158.

10. Isserlin R, Merico D, Alikhani-Koupaee R, Gramolini A, Bader GD, Emili A. Pathway analysis of dilated cardiomyopathy using global proteomic profiling and enrichment maps. Proteomics. 2010; 10:1316.

11. Wang S, Fan Z, Zhou B, Wang Y, Du P, Tan W, Lammi MJ, Guo X. Roles of glycoproteins in the diagnosis and differential diagnosis of chronic and latent Keshan disease. Molecules. 2017; 22:E746.

12. Ernoult E, Gamelin E, Guette C. Improved proteome coverage by using iTRAQ labelling and peptide OFFGEL fractionation. Proteome Sci. 2008; 6:27.

13. Zieske LR. A perspective on the use of iTRAQ TM reagent technology for protein complex and profiling studies. J Exp Bot. 2006; 57:1501-1508.

14. Sun Y, Gao C, Wang X, Yuan Y, Liu Y, Jia J. Serum quantitative proteomic analysis of patients with keshan disease based on iTRAQ labeling technique: a first term study. J Trace Elem Med Biol. 2017; 44:331-338.

15. Song HB. Dynamic analysis of the incidences and outcome of Keshan disease. Endemic Dis Bull. 1992; 7:1-6.

16. Pei J, Fu W, Yang L, Zhang Z, Liu Y. Oxidative stress is involved in the pathogenesis of Keshan disease (an endemic dilated cardiomyopathy) in China. Oxid Med Cell Longev. 2013; 2013:474203.

17. Wei HL, Pei JR, Jiang CX, Zhou LW, Lan T, Liu M, Wang T. Analysis of glutathione peroxidase 1 gene polymorphism and Keshan disease in Heilongjiang Province, China. Genet Mol Res. 2011; 10:2996-3001.

18. Mirlean N, Seus-Arrache ER, Vlasova O. Selenium deficiency in subtropical littoral pampas: environmental and dietary aspects. Environ Geochem Health. 2017.

19. Vinceti M, Filippini T, Colloni S, Bargellini A, Vergoni AV, Tsatsakis A, Ferrante M. Health risk assessment of environmental selenium: emerging evidence and challenges. Mol Med Rep. 2017; 15:3323-3335.

20. Liu X, Yang G, Wang LX, Wei J, Tan WH, Zhu YH. [Progressive risks of latent Keshan disease: a long term follow-up study]. [Article in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2016; 47:398.

21. Xiang Y, Xu Q, Tan W, He S, Shi X, Zhang W, Wang J, Wang X, Ma W. Serum biomarkers of Keshan disease assessed using a protein profiling approach based on ClinProt technique. Protein J. 2014; 33:344.

22. Sun YX, Zhu YH, Zhu JH, Niu XL, Yan C, Yang G, Lin L. [Two-dimensional gel electrophoresis map of serum proteins in patients with chronic Keshan disease]. [Article in Chinese]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2013; 44:388-392.

23. He S, Tan W, Wang J, Wang P, Xiang Y. [Screening of differentially expressed proteins in serum from subjects with Keshan disease by two-dimensional electrophoresis and mass and mass spectrometry]. [Article in Chinese]. Wei Sheng Yan Jiu. 2013; 42:424-428.

24. Boschetti E, Righetti PG. The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J Proteomics. 2009; 71:255-264.

25. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, Brücker UB, Bo N, Gebhard F, Lambris JD. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010; 185:5628-5636.

26. Daybanyrova LV, Shevchenko OP. Clinical significance levels of c-reactive protein and ceruloplasmin in patients with ischemic heart disease. Wiad Lek. 2015; 68:517.

27. Savic-Radojevic A, Pijesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel biomarkers of heart failure. Adv Clin Chem. 2016; 79:93.

28. Thielens NM, Tedesco F, Bohlsen SS, Gaboriaud C, Tenner AJ. C1q: a fresh look upon an old molecule. Mol Immunol. 2017; 89:73-83.

29. Kittl EM, Hofmann J, Hartmann G, Sebesta C, Beer F, Bauer K, Huber KR. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med. 2000; 38:205-208.

30. Cheung KJ, Tillemail K, Deforce D, Colle I, Vlierberge HV. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat. 2009; 16:418-429.

31. Lu Z, Wanf F, Liang M. SerpinC1/Antithrombin III in kidney-related diseases. Clin Sci (Lond). 2017; 131:823-831.

32. Hoen J, Ulmer H, Kilo J, Margreiter R, Grimm M, Mair P, Ruttmann E. Antithrombin III is associated with acute liver failure in patients with end-stage heart failure undergoing mechanical circulatory support. J Thorac Cardiovasc Surg. 2017; 153:1374-1382.

33. Petersen CM. Alpha 2-macroglobulin and pregnancy zone protein. Serum levels, alpha 2-macroglobulin receptors, cellular synthesis and aspects of function in relation to immunology. Dan Med Bull. 1993; 40:409-446.

34. Svendsen P, Stigbrand T, Teisner B, Folkerksen J, Dumber MG, Schouilz BV, Kemp E, Svehag SE. Immunosuppressive effect of human pregnancy zone protein on h-2 incompatible mouse heart allograft. Acta Pathol Microbiol Scand C. 1978; 86C:199-201.

35. Eicher JD, Wakabayashi Y, Vitseva O, Esa N, Yang Y, Zhu J, Freedman JE, Mcmanus DD, Johnson AD. Characterization of the platelet transcriptome by RNA sequencing in patients with acute myocardial infarction. Platelets. 2015; 27:230.

36. Chang CH, Chung CH, Kuo HL, Hsu CC, Huang TF. The highly specific platelet glycoprotein (GP) VI agonist trowaglerix impaired collagen-induced platelet aggregation
ex vivo through matrix metalloproteinase-dependent GPVI shedding. J Thromb Haemost. 2008; 6:669.

37. Zhu G, Cai G, Liu Y, Tan H, Yu C, Huang M, Wei M, Li S, Cui X, Huang D. Quantitative iTRAQ LC-MS/MS proteomics reveals transcription factor crosstalk and regulatory networks in hypopharyngeal squamous cell carcinoma. J Cancer. 2014; 5:525-536.